多烯紫杉醇联合奈达铂或顺铂治疗晚期非小细胞肺癌的疗效观察

目的对比观察多烯紫杉醇联合奈达铂或顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应。方法选取107例晚期NSCLC患者，分为奈达铂联合多烯紫杉醇治疗组（DN组）53例和顺铂联合多烯紫杉醇治疗组（DP组）54例，观察其疗效及不良反应。结果DN组有效率（41．51％，22／53）和DP组有效率（42．59％，23／54）之间差异无统计学意义（χ＾2=0．013，P〉0．05）。DN组恶心呕吐发生率（20．75％，11／53）低于DP组（62．96％，34／54），差异有显著统计学意义（χ＾2=19．554，P〈0．01），但DN组血小板下降发生率（49．06％，26／53）高于DP组（22．22％，12／54），差异有显著统计学意义（χ＾2=8．410，P〈0．01）。结论晚期NSCLC治疗中DN方案和DP方案疗效相当，但DN方案的胃肠道毒性明显轻于DP方案。

Clinical observation of docetaxel combined with nedaplatin or cisplatin in treatment of advanced non-small cell lung cancer

Objective To perform a paired observation of clinical effects of docetaxel combined with nedaplatin or cisplatin in treatment of advanced non-small cell lung cancer(NSCLC).Methods One hundred and seven patients with NSCLC were divided into two groups:DN group and DP group.In DN group,53 patients were treated with a combination of docetaxel and nedaplatin.In DP group,54 patients were treated with a combination of docetaxel and cisplatin.Results Effective rates between DN group(41.51%,22/53) and DP group(42.59%,23/54) were not significantly different(χ2=0.013,P>0.05).Additionally,gastrointestinal reaction rate in DN group(20.75%,11/53) was significantly lower than DP group(62.96%,34/54)(χ2=19.554,P<0.01).However,thrombocytopenia rate in DN group(49.06%,26/53) was significantly higher than DP group(22.22%,12/54)(χ2=8.410,P<0.01).Conclusion Both DN and DP therapeutic regimen show similar efficacy in treatment of NSCLC patients.But gastrointestinal toxic reaction in DN group is better than DP group.